Skip to main content

Table 3 HPV 16/18/31/33/45/52/58 type-specific relative contribution in precancerous cervical lesions HPV-positive, by region

From: Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease

Region HPV type Low grade High grade
HPV-positive RC 95%CI HPV-positive RC 95%CI
Africa HPV-16 517 16.8 (13.7-20.3) 251 30.3 (24.7-36.4)
HPV-18 517 8.3 (6.1-11.0) 251 9.2 (5.9-13.4)
HPV-31 432 6.5 (4.4-9.2) 245 8.2 (5.0-12.3)
HPV-33 517 8.5 (6.3-11.3) 235 8.9 (5.6-13.3)
HPV-45 432 4.4 (2.7-6.8) 245 4.1 (2.0-7.4)
HPV-52 432 11.8 (8.9-15.2) 245 11.0 (7.4-15.6)
HPV-58 517 10.8 (8.3-13.8) 251 11.2 (7.5-15.7)
Eastern Asia HPV-16 2,790 21.1 (19.6-22.6) 3,693 37.9 (36.4-39.5)
HPV-18 2,790 8.3 (7.3-9.4) 3,693 7.4 (6.5-8.3)
HPV-31 2,552 4.4 (3.7-5.3) 3,596 6.9 (6.1-7.8)
HPV-33 2,790 5.0 (4.2-5.8) 3,693 9.9 (9.0-11.0)
HPV-45 2,549 1.2 (0.8-1.7) 3,148 2.0 (1.6-2.6)
HPV-52 2,624 18.2 (16.8-19.8) 3,469 21.3 (20.0-22.7)
HPV-58 2,781 13.5 (12.3-14.9) 3,647 19.6 (18.3-20.9)
Western/Central Asia HPV-16 237 30.8 (25.0-37.1) 79 68.4 (56.9-78.4)
HPV-18 237 6.8 (3.9-10.7) 79 6.3 (2.1-14.2)
HPV-31 229 4.4 (2.1-7.9) 63 23.8 (14.0-36.2)
HPV-33 210 7.1 (4.1-11.8) 31 9.7 (2.0-25.8)
HPV-45 189 2.1 (0.6-5.8) 28 7.1 (0.9-23.5)
HPV-52 72 2.8 (0.3-9.7) 20 0.0 (0.0-16.8)
HPV-58 189 6.4 (3.3-10.8) 28 10.7 (2.3-28.2)
South/Central America HPV-16 2,692 25.1 (23.5-26.8) 1,896 52.9 (50.6-55.1)
HPV-18 2,690 6.8 (5.9-7.9) 1,886 9.4 (8.2-10.9)
HPV-31 2,504 5.2 (4.4-6.1) 1,837 10.6 (9.2-12.1)
HPV-33 2,517 7.5 (6.5-8.6) 1,776 6.5 (5.3-7.7)
HPV-45 2,166 4.5 (3.7-5.5) 1,669 4.8 (3.8-5.9)
HPV-52 2,127 5.1 (4.2-6.1) 1,587 6.3 (5.2-7.6)
HPV-58 2,220 6.9 (5.8-8.0) 1,589 9.5 (8.1-11.1)
North America HPV-16 5,532 24.7 (23.6-25.6) 4,598 56.7 (55.3-58.2)
HPV-18 5,532 9.5 (8.7-10.3) 4,598 9.6 (8.8-10.5)
HPV-31 5,532 8.9 (8.1-9.6) 4,598 13.1 (12.1-14.1)
HPV-33 5,317 4.2 (3.7-4.8) 4,598 7.6 (6.9-8.4)
HPV-45 5,415 5.6 (5.0-6.2) 4,397 4.8 (4.2-5.5)
HPV-52 4,839 10.7 (9.9-11.6) 4,205 10.3 (9.4-11.3)
HPV-58 5,213 7.6 (6.9-8.3) 4,397 6.8 (6.1-7.6)
Europe HPV-16 14,319 25.9 (25.2-26.6) 8,348 54.4 (53.3-55.5)
HPV-18 14,256 9.1 (8.6-9.6) 8,214 7.7 (7.2-8.3)
HPV-31 13,166 12.5 (12.0-13.1) 7,930 12.4 (11.6-13.1)
HPV-33 13,186 6.6 (6.2-7.1) 7,844 9.4 (8.7-10.0)
HPV-45 10,472 4.6 (4.2-5.1) 6,244 3.8 (3.3-4.3)
HPV-52 9,577 8.3 (7.8-8.9) 6,067 7.2 (6.6-7.9)
HPV-58 10,489 6.7 (6.2-7.2) 6,278 5.8 (5.2-6.4)
Oceania HPV-16 385 24.7 (20.5-29.3) 924 53.9 (50.6-57.2)
HPV-18 385 8.6 (6.0-11.8) 924 9.6 (7.8-11.7)
HPV-31 385 13.3 (10.0-17.0) 924 12.3 (10.3-14.6)
HPV-33 385 5.7 (3.6-8.5) 924 7.9 (6.2-9.8)
HPV-45 385 6.5 (4.3-9.4) 924 4.2 (3.0-5.7)
HPV-52 385 11.4 (8.4-15.0) 924 12.2 (10.2-14.5)
HPV-58 385 9.1 (6.4-12.4) 924 5.8 (4.4-7.6)
  1. Low-grade, includes ASCUS, LSIL and CIN1; High-grade, includes HSIL, CIN2 and CIN3.
  2. “RC”: Relative Contribution; “95%CI”: 95% Confidence Interval.
  3. Additional information: HPV type specific relative contribution: Numerator = includes either single or multiple infections, thus the total sum of % can exceed 100%; Denominator = ”Tested” cases that stands for the HPV/DNA positive cases from studies testing for the HPV type in question, thus denominators vary by type.
  4. The data source does not give specific information for HPV 6 and 11.
  5. 17. Data from Guan et al., IJC, 2012.